Immunity wanes, and some people's immune systems never mount a strong response
By late October 2021, the World Health Organization had formally approved six COVID-19 vaccines, each carrying its own promise and its own limits, reflecting the uneven terrain of a pandemic that had forced science to move faster than certainty. The WHO's Strategic Advisory Group of Experts crafted guidance that acknowledged two enduring truths: immunity is not permanent, and not all bodies respond equally. In recommending booster doses for the immunocompromised and, in some cases, the elderly, the organization was not revising its confidence in the vaccines — it was honoring the complexity of human biology and the humility that good medicine requires.
- Six approved vaccines offer wildly different levels of protection — from 51% to 95% — forcing health authorities to tailor guidance rather than issue a single universal prescription.
- Waning immunity and the vulnerability of immunocompromised populations created urgent pressure to move beyond primary dosing schedules before the science of boosters was fully settled.
- Countries like the United States and Chile moved ahead of WHO recommendations, launching broad third-dose campaigns that the organization had not yet universally endorsed, exposing the tension between global guidance and national urgency.
- Vaccines not yet approved by the WHO — including Russia's Sputnik V and India's Covaxin — remained in widespread use across Latin America and beyond, leaving millions in a regulatory gray zone.
- The WHO's framework is landing as a baseline, not a ceiling: a structured but flexible foundation that national health systems are already building upon, and in some cases surpassing.
By late October 2021, the WHO had approved six COVID-19 vaccines, each with its own efficacy profile and dosing logic. They ranged from Sinovac's 51 percent effectiveness against symptomatic infection to Pfizer-BioNTech's 95 percent — and the guidance reflected those differences in concrete terms: how many shots, how far apart, and for whom.
The WHO's expert group built its recommendations around a difficult reality: immunity fades, and some immune systems never respond strongly to begin with. Booster doses became standard across all six vaccines, at minimum for immunocompromised individuals. For Sinopharm and Sinovac, the WHO went further, recommending boosters for anyone over 60, acknowledging that age compounded the already modest protection those vaccines offered.
Each vaccine told a different story. Moderna required only a single primary dose — an unusual distinction. Pfizer-BioNTech, the only vaccine cleared for adolescents as young as 12, required two doses three to four weeks apart. Oxford-AstraZeneca and Janssen each required two doses, while Sinopharm and Sinovac followed similar two-dose schedules with slightly different spacing. All were delivered as 0.5-milliliter intramuscular injections.
The WHO's guidance also drew careful lines around who could receive each vaccine. Pregnant women were generally advised against vaccination, though individual medical judgment was permitted when benefits appeared to outweigh risks. Nursing mothers faced no such restriction. Sinopharm and Sinovac were recommended only for adults between 18 and 60, with special monitoring required for older recipients of Sinovac.
The real-world picture was more complicated. Several vaccines already in use — Sputnik V, CanSino, Covaxin — had not yet received WHO emergency authorization, leaving their recipients outside the organization's formal framework. Meanwhile, the United States and Chile had already launched broad third-dose campaigns, moving well beyond the WHO's baseline. The organization's recommendations were a floor, not a ceiling — and nations were already building higher.
By late October 2021, the World Health Organization had given its stamp of approval to six COVID-19 vaccines, each with its own efficacy profile, dosing schedule, and population recommendations. The vaccines ranged widely in their protective power—from Sinovac's modest 51 percent effectiveness against symptomatic infection to Pfizer-BioNTech's 95 percent—and the WHO's guidance reflected those differences in practical terms: how many shots, how far apart, and for whom.
The organization's Strategic Advisory Group of Experts had settled on a framework that acknowledged a hard reality of the pandemic: immunity wanes, and some people's immune systems never mount a strong response in the first place. For that reason, booster doses became part of the standard recommendation across all six vaccines, at minimum for people whose immune systems were compromised by disease or medication. For the two Chinese vaccines—Sinopharm and Sinovac—the WHO also recommended boosters for anyone over 60, recognizing that age itself was a risk factor that their efficacy data suggested warranted extra protection.
The vaccines themselves told different stories. Oxford-AstraZeneca and Janssen required two doses, though Janssen's came as a single shot followed by a booster for the immunocompromised. Moderna needed only one primary dose, an unusual advantage that set it apart. Pfizer-BioNTech, approved for people as young as 12, required two doses spaced three to four weeks apart. Both Sinopharm and Sinovac required two doses as well, though the spacing differed slightly—three to four weeks for Sinopharm, two to four for Sinovac. All were delivered as intramuscular injections of 0.5 milliliters.
The WHO's guidance came with important caveats about who could receive each vaccine. Pfizer-BioNTech was the only one cleared for adolescents, approved for those 12 and older. The others were restricted to adults 18 and up, pending further study. Sinopharm and Sinovac carried an additional limitation: the WHO recommended them only for people between 18 and 60 years old, with Sinovac requiring special monitoring if given to older adults. Pregnant women were generally discouraged from vaccination across all six, though the WHO left room for individual medical judgment if the benefits seemed to outweigh the risks. Nursing mothers, by contrast, could receive any of the vaccines without interrupting breastfeeding.
The real-world picture was messier than the WHO's orderly table of recommendations. Several other vaccines were already in use across Latin America and beyond—Sputnik V from Russia, CanSino from China, Covaxin from India, and others—but the WHO had not yet approved them for emergency use. Sputnik V seemed likely to gain approval by year's end, but the others remained in limbo. More significantly, individual countries were already moving beyond the WHO's baseline guidance. The United States and Chile had both launched campaigns to vaccinate most of their populations with a third dose in the second half of 2021, a step the WHO had not universally recommended. The organization's guidelines were a floor, not a ceiling; each nation was free to build its own, more stringent protocols on top.
What emerged from the WHO's careful documentation was a portrait of six different tools, each with distinct strengths and limitations. Moderna and Pfizer-BioNTech offered the highest efficacy but required careful cold-chain management. The viral vector vaccines—Oxford-AstraZeneca and Janssen—were easier to store and distribute but offered somewhat lower protection. The inactivated vaccines from China occupied a middle ground: Sinopharm at 79 percent efficacy, Sinovac at 51 percent but with remarkable effectiveness against severe disease and hospitalization. None was perfect. All required boosters for vulnerable populations. And all depended, ultimately, on the willingness of health systems to implement the guidance and populations to accept it.
Notable Quotes
The WHO's guidelines were a floor, not a ceiling; each nation was free to build its own, more stringent protocols on top.— WHO guidance framework
The Hearth Conversation Another angle on the story
Why did the WHO bother approving six different vaccines when they could have just picked the best one?
Because the best vaccine on paper isn't always the best vaccine in practice. Pfizer and Moderna need ultra-cold storage. Oxford-AstraZeneca and Janssen are easier to ship and store. In countries without sophisticated cold chains, that difference is everything.
So the Chinese vaccines—Sinopharm and Sinovac—they're weaker, then?
Weaker at preventing infection, yes. Sinovac is only 51 percent effective at stopping symptomatic disease. But it's 100 percent effective at preventing severe illness and hospitalization. For a health system trying to keep hospitals from collapsing, that's not weak at all.
The booster recommendations seem to vary a lot between vaccines. Why?
The data told different stories. With Pfizer and Moderna, the evidence was strong enough that the WHO only recommended boosters for immunocompromised people. But Sinopharm and Sinovac showed enough decline in protection over time that older adults needed boosters too.
And countries like the US and Chile just ignored the WHO and gave boosters to everyone anyway?
Not ignored—exceeded. The WHO sets a minimum standard based on the evidence available at that moment. Countries can decide their own risk tolerance is lower and do more. That's not a failure of the system; it's how it's supposed to work.
What about all those other vaccines that weren't approved—Sputnik, Covaxin, the others?
They existed, they were being used, but the WHO hadn't reviewed the data thoroughly enough to vouch for them. Sputnik V was close. The others—there were questions about the evidence, or the WHO simply hadn't gotten to them yet. Approval takes time.